RNDO-Program 3

N/A

Report date: 2026/03/19 17:03:38

Base Information

Drug NameRNDO-Program 3

Drug Alias NameRNDO-Program 3

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsT-cell-specific surface glycoprotein CD28 modulators

TargetsT cell surface glycoprotein CD3T-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsEndometrial Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRondo Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesRondo Therapeutics

Inactive CompaniesN/A

Active IndicationsEndometrial Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A